Literature DB >> 21179104

Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers.

Atsushi Watanabe1, Tatsuki Karasugi, Hideaki Sawai, Banyar Than Naing, Shiro Ikegawa, Hideo Orimo, Takashi Shimada.   

Abstract

Hypophosphatasia (HPP) is an inherited disorder caused by mutations in ALPL that encodes an isozyme of alkaline phosphatase (ALP), TNSALP. One of the most frequent ALPL mutations is c.1559delT, which causes the most severe HPP, the perinatal (lethal) form (pl-HPP). c.1559delT has been found only in Japanese and its prevalence is suspected to be high; however, the allele frequency of c.1559delT in Japanese remains unknown. We designed a screening system for the mutation based on high-resolution melting curve analysis, and examined the frequency of c.1559delT. We found that the c.1559delT carrier frequency is 1/480 (95% confidence interval, 1/1562-1/284). This indicates that ∼1 in 900 000 individuals to have pl-HPP caused by a homozygous c.1559delT mutation. In our analysis, the majority of c.1559delT carriers had normal values of HPP biochemical markers, such as serum ALP and urine phosphoethanolamine. Our results indicate that the only way to reliably detect whether individuals are pl-HPP carriers is to perform the ALPL mutation analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21179104     DOI: 10.1038/jhg.2010.161

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  21 in total

Review 1.  Hypophosphatasia: clinical manifestation and burden of disease in adult patients.

Authors:  Francesco Conti; Lorenzo Ciullini; Giuseppe Pugliese
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

Review 2.  Dental manifestation and management of hypophosphatasia.

Authors:  Rena Okawa; Kazuhiko Nakano
Journal:  Jpn Dent Sci Rev       Date:  2022-07-02

3.  Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures.

Authors:  Dina Belachew; Traci Kazmerski; Ingrid Libman; Amy C Goldstein; Susan T Stevens; Stephanie Deward; Jerry Vockley; Mark A Sperling; Arcangela L Balest
Journal:  JIMD Rep       Date:  2013-03-12

Review 4.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

Review 5.  Alkaline Phosphatase Replacement Therapy.

Authors:  Maria Luisa Bianchi; Silvia Vai
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

6.  Successful gene therapy in utero for lethal murine hypophosphatasia.

Authors:  Hanako Sugano; Tae Matsumoto; Koichi Miyake; Atsushi Watanabe; Osamu Iijima; Makoto Migita; Sonoko Narisawa; José Luis Millán; Yoshitaka Fukunaga; Takashi Shimada
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

7.  Interaction effect between handedness and CNTNAP2 polymorphism (rs7794745 genotype) on voice-specific frontotemporal activity in healthy individuals: an fMRI study.

Authors:  Michihiko Koeda; Atsushi Watanabe; Kumiko Tsuda; Miwako Matsumoto; Yumiko Ikeda; Woochan Kim; Amane Tateno; Banyar Than Naing; Hiroyuki Karibe; Takashi Shimada; Hidenori Suzuki; Masato Matsuura; Yoshiro Okubo
Journal:  Front Behav Neurosci       Date:  2015-04-20       Impact factor: 3.558

8.  A Case of Vitamin D Deficiency without Elevation of Serum Alkaline Phosphatase in a Carrier of Hypophosphatasia.

Authors:  Kumihiro Matsuo; Tokuo Mukai; Akiko Furuya; Shigeru Suzuki; Yusuke Tanahashi; Hiroshi Azuma
Journal:  Clin Pediatr Endocrinol       Date:  2013-10-26

Review 9.  Pathophysiology of hypophosphatasia and the potential role of asfotase alfa.

Authors:  Hideo Orimo
Journal:  Ther Clin Risk Manag       Date:  2016-05-17       Impact factor: 2.423

10.  Clinical and Genetic Findings of Turkish Hypophosphatasia Cases.

Authors:  Halil Sağlam; Şahin Erdöl; Sevil Dorum
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.